



News Release

Suven's Alzheimer drug candidate SUVN-502 successfully completed all chronic toxicological (tox) studies and demonstrated very high margin of safety (MOS)

HYDERABAD, INDIA (May 18, 2011) – Suven Life Sciences Ltd (Suven) announces today that their clinical drug candidate SUVN-502 completed all the long term chronic studies like 6-month rat tox, 9-month dog tox and developmental tox studies like prenatal development tox in rats and rabbits, embryo-fetal development tox in rats and male fertility tox in rats **very successfully and demonstrated very high margin of safety (MOS)**. These regulatory tox studies are essential for FDA approval to initiate human phase 2a clinical trials in patient population.

SUVN-502 has been tested in human Phase 1 trials in Switzerland and demonstrated to be very safe at all doses and durations tested with excellent bioavailability. **The next stage of testing will be proof of concept Phase 2 a clinical trials in patients with Alzheimer's / Schizophrenia disease.**

"We are very pleased with the excellent outcome of all chronic and developmental tox studies for our clinical candidate SUVN-502 which is being developed for CNS disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia and **the potential market opportunity is more than \$20 billion globally** says Venkat Jasti CEO of Suven Life Sciences.

We have received several interests for SUVN-502 from pharmaceutical companies and **anticipate probable partnering in the near future**. Simultaneously we are actively engaged to file an Investigational New Drug application (IND) with the US FDA to support initiation of phase 2 a **Proof of Concept (PoC) clinical trials in human patients during this year using this tox data.**

For more information on Suven, please visit our Web site at www.suven.com

Safe Harbor Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

Regd. Off: SDE Serene Chambers, 6th Floor, Road 5, Banjara Hills Hyderabad 500032
Tel: 9140 2354 1142 Fax: 9140 2354 1152 Email: info@suven.com

